Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”

Bibliographic Details
Main Authors: Jing Nianshui, Li Xinnan
Format: Article
Language:English
Published: De Gruyter 2021-07-01
Series:Open Medicine
Online Access:https://doi.org/10.1515/med-2021-0331
_version_ 1818025210473873408
author Jing Nianshui
Li Xinnan
author_facet Jing Nianshui
Li Xinnan
author_sort Jing Nianshui
collection DOAJ
first_indexed 2024-12-10T04:12:29Z
format Article
id doaj.art-8eac74e283644da9a8eeee1826023936
institution Directory Open Access Journal
issn 2391-5463
language English
last_indexed 2024-12-10T04:12:29Z
publishDate 2021-07-01
publisher De Gruyter
record_format Article
series Open Medicine
spelling doaj.art-8eac74e283644da9a8eeee18260239362022-12-22T02:02:41ZengDe GruyterOpen Medicine2391-54632021-07-011611082108210.1515/med-2021-0331Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”Jing Nianshui0Li Xinnan1Department of Pharmacy, Jinan No. 2 People’s Hospital, Jinan 250001, Shandong, ChinaDepartment of Pharmacy, Jinan No. 2 People’s Hospital, Jinan 250001, Shandong, Chinahttps://doi.org/10.1515/med-2021-0331
spellingShingle Jing Nianshui
Li Xinnan
Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
Open Medicine
title Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
title_full Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
title_fullStr Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
title_full_unstemmed Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
title_short Retraction on “Dihydromyricetin attenuates inflammation through TLR4/NF-kappa B pathway”
title_sort retraction on dihydromyricetin attenuates inflammation through tlr4 nf kappa b pathway
url https://doi.org/10.1515/med-2021-0331
work_keys_str_mv AT jingnianshui retractionondihydromyricetinattenuatesinflammationthroughtlr4nfkappabpathway
AT lixinnan retractionondihydromyricetinattenuatesinflammationthroughtlr4nfkappabpathway